MedTrace Logo

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

NCT05572645 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 333

Last updated 2024-02-26

No results posted yet for this study

Summary

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Conditions

Interventions

DRUG

Pyrotinib Plus Trastuzumab

treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)

DRUG

Pertuzumab Plus Trastuzumab

treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-09-01
Completion
2023-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572645 on ClinicalTrials.gov